-
Article
Open AccessIncidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting....
-
Article
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities
Myelofibrosis (MF) is commonly diagnosed in older individuals and has not been extensively studied in young patients. Given the infrequent diagnosis in young patients, analyzing this cohort may identify factor...
-
Article
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)
-
Article
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
-
Article
Open AccessEvaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
Myelodysplastic syndromes (MDS) treated with DNMTI therapy have responses according to the 2006 IWG response criteria. CR responses have had the strongest association with OS. Recently, CR with partial hematol...
-
Article
Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia
-
Article
Open AccessMyelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
The current World Health Organization (WHO) classification of myeloid malignancies includes myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) as a distinct e...
-
Article
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data
In the MYF2001 trial, treatment of Janus kinase (JAK) inhibitor-relapsed/refractory intermediate-2 or high-risk myelofibrosis (MF) with imetelstat 9.4 mg/kg every 3 weeks demonstrated encouraging median overal...
-
Reference Work Entry In depth
Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematologic malignancy of the elderly defined by morphologic dysplasia and ineffective hematopoiesis, resulting in uni- or multilineage cytopenias. Dri...
-
Article
Open AccessValidation of the Khorana score in acute myeloid leukemia patients: a single-institution experience
Although patients with acute myeloid leukemia (AML) were shown to have an increased risk of thrombosis, no thrombosis risk assessment scoring system has been developed for AML patients. The Khorana Risk Score ...
-
Article
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML
Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous neoplasm in which JAK2 inhibition has demonstrated reductions in inflammatory cytokines and promising clinical activity. We hypothesize that...
-
Living Reference Work Entry In depth
Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematologic malignancy of the elderly defined by morphologic dysplasia and ineffective hematopoiesis, resulting in uni- or multilineage cytopenias. Dri...
-
Article
Open AccessGender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
-
Article
Open AccessValidation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
-
Article
Open AccessASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
-
Article
Open AccessConnect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent cytopenia...
-
Article
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
Tyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myeloid leukemia (CML). While TKIs have less toxicity than previous treatments, they have side effects that can impact quality of life (...
-
Chapter
The Hematopoietic Growth Factors in the Myelodysplastic Syndromes
The myelodysplastic syndromes (MDSs) are a heterogeneous group of hematopoietic stem cell malignancies that are characterized by abnormal morphology and impaired bone marrow maturation resulting in progressive...
